STOCK TITAN

Adc Therapeutics SA - ADCT STOCK NEWS

Welcome to our dedicated news page for Adc Therapeutics SA (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adc Therapeutics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adc Therapeutics SA's position in the market.

Rhea-AI Summary
ADC Therapeutics completes dose escalation in Phase 1b trial for ZYNLONTA in combination with bispecific antibodies with promising results and initiates Part 2 dose expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
-
Rhea-AI Summary
ADC Therapeutics SA (ADCT) will host a virtual Research Investor Event on April 9, 2024, featuring presentations from the CEO and CSO on the company's exatecan-based antibody drug conjugate platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics SA announces grants of options to purchase common shares to new employees as employment inducement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
Rhea-AI Summary
ADC Therapeutics (ADCT) reported net sales of $16.6 million in 4Q 2023 and $69.1 million for FY 2023. Operating expenses decreased by 21% year-over-year. The company's pipeline is progressing with dose escalation in LOTIS-7 and screening patients for ADCT-601 targeting AXL in pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.36%
Tags
-
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT) CEO to participate in a fireside chat at Guggenheim 5th Annual Healthy Altitudes Summit. Webcast details provided for investor access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT) will host a conference call to report financial results for Q4 and year-end 2023, along with business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
conferences earnings
Rhea-AI Summary
ADC Therapeutics SA announces acceptance of abstracts for presentation at AACR Annual Meeting, showcasing preclinical data supporting future clinical development of ADCs targeting Claudin-6 and NaPi2b, along with independent studies on ADCT-601 targeting AXL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
Rhea-AI Summary
ADC Therapeutics SA (ADCT) CEO to present at TD Cowen 44th Annual Health Care Conference. Live webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics SA (ADCT) regains compliance with NYSE listing minimum price criteria, averting potential delisting. The company's common shares closed above $1.00, resolving the previous noncompliance issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
none
Rhea-AI Summary
ADC Therapeutics SA (ADCT) expects 4Q 2023 net sales of ZYNLONTA to be ~$16.5 million, with positive clinical trial results and a cash runway into 4Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
none
Adc Therapeutics SA

NYSE:ADCT

ADCT Rankings

ADCT Stock Data

366.43M
62.97M
29%
41.17%
1.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Epalinges

About ADCT

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.